You are here: Home / Our people / Our academics / Clinical Professor Harry Iland 

Publications list for Clinical Professor Harry Iland

2012 | 2009 | 2007

2012

   
  • Brown, C., Larsen, S., Iland, H., Joshua, D., Gibson, J. (2012), Leukaemias into the 21st century: part 1: the acute leukaemias. Internal Medicine Journal. 42(11), 1179-1186. [Abstract]
  • Khoo, T., Catalano, A., Supple, S., Chong, L., Yeoh, S., Yeung, S., Iland, H. (2012), Hyperpigmentation of the hard palate associated with imatinib therapy for chronic myeloid leukemia with a genetic variation in the proto-oncogene c-KIT. Leukemia & Lymphoma. 54(1), 186-188. [Abstract]
  • Iland, H., Bradstock, K., Supple, S., Catalano, A., Collins, M., Hertzberg, M., Browett, P., Grigg, A., Firkin, F., Hugman, A., Reynolds, J., Di Iulio, J., Tiley, C., Taylor, K., Filshie, R., Seldon, M., Taper, J., Szer, J., Moore, J., Bashford, J., Seymour, J. (2012), All-trans-retinoic acid, idarubicin, and intravenous arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). Blood. 120(8), 1570-1580. [Abstract]
  • Iland, H., Bradstock, K., Seymour, J., Hertzberg, M., Grigg, A., Taylor, K., Catalano, J., Cannell, P., Horvath, N., Deveridge, S., Browett, P., Brighton, T., Chong, L., Springall, F., Ayling, J., Catalano, A., Supple, S., Collins, M., Di Iulio, J., Reynolds, J. (2012), Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemia. Haematologica. 97(2), 227-234. [Abstract]
  • Ling, S., Lau, E., Al-Shabeeb, A., Nikolic, A., Catalano, A., Iland, H., Horvath, N., Ho, P., Harrison, S., Fleming, S., Joshua, D., Allen, J. (2012), Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1. Haematologica. 97(1), 64-72. [Abstract]

2009

   
Back to Top
  • de Zwaan, S., Iland, H., Damian, D. (2009), Treatment of refractory pyoderma gangrenosum with intravenous immunoglobulin. The Australasian Journal of Dermatology. 50(1), 56-59. [Abstract]

2007

   
Back to Top
  • Catalano, A., Dawson, M., Somana, K., Opat, S., Schwarer, A., Campbell, L., Iland, H. (2007), The PRKAR1A gene is fused to RARA in a new variant acute promyelocytic leukemia. Blood. 110(12), 4073-6. [Abstract]
  • Sanders, J., Crawford, B., Gibson, J., Joy Ho, P., Iland, H., Joshua, D. (2007), Is there a case for the early use of bisphosphonates in smouldering myeloma and MGUS? (Bisphosphonates in SMM & MGUS). International journal of laboratory hematology. , 395-397. [Abstract]
  • Young, G., Iland, H. (2007), Clinical perspectives in lymphoma. Internal medicine journal. 37(7), 478-484. [Abstract]
  • Losco, P., Brown, R., Iland, H., Uhr, E., Lee, L., Joshua, D. (2007), An evaluation of the technical performance and clinical applications of the Beckman Coulter Access® Erythropoietin immunoassay. Australian Journal of Medical Science. 28(4), 139-144.